Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New technology shows promise against resistant staph infections

04.05.2009
Particles infused with nitric oxide are antibacterial and promote wound healing

Scientists at Albert Einstein College of Medicine of Yeshiva University have combined their revolutionary new drug-delivery system with a powerful antimicrobial agent to treat potentially deadly drug-resistant staph infections in mice. The study is published this month in the online version of the Journal of Investigative Dermatology.

Staphylococcus aureus bacteria cause the majority of superficial and invasive skin infections, resulting in more than 11 million outpatient/emergency room visits and 464,000 hospital admissions annually in the U.S. Staph are also notorious for infecting patients while they're in the hospital for other reasons. Staph infections can be deadly if the bacteria invade the bloodstream, heart, lungs, or urinary tract. As more strains of staph become resistant to common antibiotics, the need for new treatments has become urgent.

The drug-delivery system, developed by Einstein scientists, consists of biocompatible nanoparticles — each smaller than a grain of pollen — that can carry tiny payloads of various drugs or other medically useful substances and release them in a controlled and sustained manner. In this study, the nanoparticles were designed to transport and slowly release nitric oxide (NO) gas.

The nanoparticle technology was developed by Joel M. Friedman, M.D., Ph.D., professor of physiology & biophysics and of medicine at Einstein, and his son, Adam Friedman, M.D., an incoming chief resident in the division of dermatology at Einstein. The Friedmans were co-senior authors of the study along with Joshua D. Nosanchuck, M.D., associate professor in the departments of medicine and microbiology & immunology at Einstein.

NO is produced by many cells throughout the body and has several important biological functions including killing bacteria, healing wounds, and increasing blood flow by dilating blood vessels. But harnessing NO's therapeutic potential has proven difficult. "The problem is that nitric oxide is very short-lived and, until now, methods to deliver it to targeted tissues in the proper dosages have proven elusive," says Dr. Joel Friedman.

The Friedmans solved the problem of controlled and sustained NO delivery by developing a method of generating NO from sodium nitrite within a novel nanoparticle formulation. The nanoparticles are stable when dry and resemble a fine white powder when present in large amounts.

"As the particles take on water, they loosen up and the nitric oxide slowly trickles out, releasing specific amounts of the gas — which is exactly what happens in your body," says Dr. Friedman.

The present study involved collaboration between the Friedman laboratory and Dr. Nosanchuk's laboratory. Mice whose skin was infected with methicillin-resistant Staphylococcus aureus, or MRSA, were treated topically with NO-containing nanoparticles or with nanoparticles devoid of NO. A third group received no treatment at all.

The NO-containing nanoparticles proved highly effective. After seven days, infected wounds in the group treated with the NO-containing nanoparticles were significantly improved and smaller than lesions in the two other groups. In addition, bacterial counts were significantly lower in the NO-treated group compared with the other groups, and the NO-treated group showed evidence of accelerated wound healing both visually and microscopically.

After further refining their nanoparticles, the Einstein team plans to test them in clinical trials against MRSA and other infections. Dr. Friedman is confident that the therapy will be safe for human use. "To date there have been no indication of toxicity in any of the numerous animal studies," he says.

In another potential use, Einstein scientists at the annual meeting of the American Urological Association earlier this week reported that nanoparticles carrying either NO or the drug tadalafil (Cialis) show promise as a topical treatment for erectile dysfunction.

The paper, "Antimicrobial and Healing Efficacy of Sustained Release Nitric Oxide Nanoparticles Against Staphylococcus Aureus Skin Infection," was published April 23, 2009, in the online version of the Journal of Investigative Dermatology. Lead authors of the study were Luis R. Martinez, Ph.D., an Einstein research associate, and George Han, an M.D-Ph.D. candidate at Einstein. Other Einstein contributors were Manju Chacko, Mircea Radu Mihu, Marc Jacobson, and Phil Gialanella.

Einstein has filed patent applications covering the nanoparticles and their pharmacological applications for delivering nitric oxide and other compounds.

About Albert Einstein College of Medicine of Yeshiva University

Albert Einstein College of Medicine of Yeshiva University is one of the nation's premier centers for research, medical education and clinical investigation. It is the home to some 2,000 faculty members, 750 M.D. students, 350 Ph.D. students (including 125 in combined M.D./Ph.D. programs) and 380 postdoctoral investigators. Last year, Einstein received more than $130 million in support from the NIH. This includes the funding of major research centers at Einstein in diabetes, cancer, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Through its extensive affiliation network involving five hospital centers in the Bronx, Manhattan and Long Island – which includes Montefiore Medical Center, The University Hospital and Academic Medical Center for Einstein – the College runs one of the largest post-graduate medical training program in the United States, offering approximately 150 residency programs to more than 2,500 physicians in training.

Deirdre Branley | EurekAlert!
Further information:
http://www.aecom.yu.edu

More articles from Health and Medicine:

nachricht The genes are not to blame
20.07.2018 | Technische Universität München

nachricht Targeting headaches and tumors with nano-submarines
20.07.2018 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Future electronic components to be printed like newspapers

A new manufacturing technique uses a process similar to newspaper printing to form smoother and more flexible metals for making ultrafast electronic devices.

The low-cost process, developed by Purdue University researchers, combines tools already used in industry for manufacturing metals on a large scale, but uses...

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

A smart safe rechargeable zinc ion battery based on sol-gel transition electrolytes

20.07.2018 | Power and Electrical Engineering

Reversing cause and effect is no trouble for quantum computers

20.07.2018 | Information Technology

Princeton-UPenn research team finds physics treasure hidden in a wallpaper pattern

20.07.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>